Cargando…
How I treat gastric adenocarcinoma
Gastric and gastro-oesophageal junction cancer (GC) represents a worldwide problem, this being the fifth most common malignancy. The fragility of patients with GC together with the aggressiveness of this tumour makes it as one of the most difficult neoplasias to manage. This article summarises the m...
Autores principales: | Alsina, Maria, Miquel, Josep Maria, Diez, Marc, Castro, Sandra, Tabernero, Josep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615878/ https://www.ncbi.nlm.nih.gov/pubmed/31354966 http://dx.doi.org/10.1136/esmoopen-2019-000521 |
Ejemplares similares
-
Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
por: Alsina, Maria, et al.
Publicado: (2022) -
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
por: Tabernero, Josep, et al.
Publicado: (2021) -
Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report
por: Mirallas, Oriol, et al.
Publicado: (2022) -
Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010) -
Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations
por: Tabernero, Josep
Publicado: (2019)